ஐரோப்பிய மீட்பு ப்ரோக்ராம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஐரோப்பிய மீட்பு ப்ரோக்ராம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஐரோப்பிய மீட்பு ப்ரோக்ராம் Today - Breaking & Trending Today

MCA presents proposals to further boost NRP


KUALA LUMPUR: MCA has presented its proposal to sharpen several aspects of the National Recovery Plan (NRP).
The proposals were presented to Finance Minister Tengku Datuk Seri Zafrul Aziz by MCA secretary-general Datuk Chong Sin Woon, MCA deputy secretary-general Dr Pamela Yong and MCA spokesperson Chan Quin Er in a meeting yesterday.
“In working towards an inclusive economy based on the principles of shared prosperity, recovery efforts should be calibrated to those who need it most,” said the party in a statement after the meeting, where the MCA delegation managed to have a meaningful conversation with the Finance Minister and his team on topics pertaining to national recovery strategies. ....

Kuala Lumpur , Pamela Yong , Zafrul Aziz , Bantuan Bakul Makanan , National Recovery Plan , European Recovery Programme , Wage Subsidy Programme , Datuk Chong Sin Woon , Finance Minister , Marshall Plan , Marshall Plan Type , Marshall Plan , Second World , Employment Insurance System , Food Basket , Unemployment Insurance Scheme , குவாலா லம்பூர் , பமீலா யோங் , ஜப்ருள் அஜிஸ் , தேசிய மீட்பு திட்டம் , ஐரோப்பிய மீட்பு ப்ரோக்ராம் , ஊதியம் மானியம் ப்ரோக்ராம் , நிதி அமைச்சர் , மார்ஷல் திட்டம் வகை , மார்ஷல் திட்டம் , இரண்டாவது உலகம் ,

NeRRe Therapeutics raises £20 million in a Series B2


July
2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional £20 million in a Series B2 financing round.
Having demonstrated proof of efficacy in patients with refractory or unexplained chronic cough
i, NeRRe will now continue the clinical development of orvepitant in chronic cough caused by IPF, a rare type of interstitial lung disease
ii. A dominant symptom of this severe progressive fibrotic pulmonary disease, in a high proportion of these terminally ill patients, is an uncontrolled, persistent, and disabling cough. ....

New York , United States , Hong Kong , United Kingdom , San Francisco , University Of Southern California , Trowerm Pawsey , Los Angeles , Mary Kerr , Javier Garcia , Advent Life Sciences , United Kingdom Government Future Fund , European Recovery Programme , British Business Bank , Dutch Venture Initiative , Consilium Strategic Communications , Columbus Venture Partners , Fountain Healthcare Partners , Forbion Capital Partners , United Kingdom Government , Maher Professor , Interstitial Lung Disease , Keck School , Southern California , General Partner , Venture Partners ,